SPRO Earnings

SPRO reported its FY2025Q3 earnings on 2025-11-13, showcasing a revenue of 5.44M against an estimate of , resulting in a 0% surprise. The EPS was -0.13, surpassing the expected -0.25 by 48% . The stock experienced a -1.23% price change on the earnings day and a -2.46% change over the next five days, reflecting market reactions to the results.

Following SPRO's FY2025Q3 earnings announcement on 2025-11-13, the stock price moved by -1.23% on the day of the release. Over the subsequent five days, it saw a -2.46% change. Historically, SPRO's stock price tends to shift by an average of -4.15% in the 10 days leading up to earnings and +15.76% in the 10 days following, providing insight into potential market.

For , analysts estimate SPRO’s annual revenue to reach , while the EPS is projected at -0.20. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between SPRO's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, SPRO's stock price typically moves by -4.15% in the 10 days before its earnings and +15.76% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.20 and revenue of .

The earnings call reveals significant financial challenges, with a drastic revenue decline and increased losses. The clinical trial for SPR720 failed to meet its primary endpoint, posing risks. The lack of a shareholder return plan and increased R&D expenses further dampen sentiment. The Q&A section highlights management's uncertainty and lack of clear guidance, exacerbating concerns. Overall, the combination of financial struggles, clinical setbacks, and unclear strategic direction suggests a strong negative sentiment, likely leading to a significant stock price decline.